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Role of Peroxisome Proliferator-Activated Receptor γ and
Estrogen Receptors in Mediating the Anti-Mitogenic Actions of
Phytoestrogens
Abstract
Most Western countries face high and increasing rates of cardiovascular disease (CVD). Each year,
heart disease kills more people than cancer. The increasing risk of CVD in woman after postmenopausal
changes suggests that estrogen has cardioprotective effects. It is well known that estrogen binds to
estrogen receptors (ER) and mediates its effects via different pathways and thereby influences various
systems in the male and female physiology.  Phytoestrogens, natural constituents of many plants, seeds
and grains are oestrogen like ligands with numerous effects to the human body. They are similar to
estrogens and bind to ERs, they are supposed to mimic the effects of estrogens and mediate these
acitivities via ERs. However, recent findings suggest that phytoestrogens bind to PPAR- γ receptors.
Together with the fact, that the protective effects of the phytoestrogen genistein are not blocked by ER
antagonist and that PPAR- γ agonists are also cardioprotective we investigated, whether the protective
action of phytoestrogens may be PPAR- γ mediated. 
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Abstract 
 
Introduction 
 
Most Western countries face high and increasing rates of cardiovascular disease (CVD). Each 
year, heart disease kills more people than cancer. The increasing risk of CVD in woman after 
postmenopausal changes suggests that estrogen has cardioprotective effects. It is well known 
that estrogen binds to estrogen receptors (ER) and mediates its effects via different pathways 
and thereby influences various systems in the male and female physiology.  
Phytoestrogens, natural constituents of many plants, seeds and grains are oestrogen like 
ligands with numerous effects to the human body. They are similar to estrogens and bind to 
ERs, they are supposed to mimic the effects of estrogens and mediate these acitivities via 
ERs. However, recent findings suggest that phytoestrogens bind to PPAR- γ receptors. 
Together with the fact, that the protective effects of the phytoestrogen genistein are not 
blocked by ER antagonist and that PPAR- γ agonists are also cardioprotective we 
investigated, whether the protective action of phytoestrogens may be PPAR- γ mediated. 
 
Material and Methods 
 
Human aortic smooth muscle cells were harvested and cultured under standard conditions and 
plated in 24 well tissue culture dishes. Cultures were either treated with genistein, daidzein, 
equol, resveratrol and rosiglitazone. Each experiment was performed with or without the use 
of oestrogen receptor antagonist ICI 182,780 and PPAR- γ antagonist GW 9662.  
After 20h different experiments were performed. Collagen synthesis, DNA synthesis and total 
cell numbers were measured from standardized numbers of SMCs from each cell culture. 
SMCs with no treatment served as control. 
 
Results 
 
SMCs treated with genistein showed a significant inhibition of DNA synthesis, while 
additional PPAR-γ antagonist treatment lead to reversal of the inhibitory effect of genistein on 
DNA synthesis. In presence of oestrogen receptor antagonist ICI182780 the inhibitory effects 
of genistein remained unchanged.  
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Collagen synthesis was significantly reduced in SMCs treated with genistein alone, while 
these effects were reversed in the presence of PPAR-γ receptor antagonist. Again, the 
inhibitory effects of genistein on collagen synthesis were not abrogated in presence of 
oestrogen receptor antagonist. SMC proliferation assays showed a decreased level of 
proliferation rate under genistein treatment and these effects were not altered by ER 
antagonist. Genistein treatment inhibited SMC proliferation and these effects were blocked by 
PPAR-γ receptor antagonist. 
Compared to rosiglitazone, genistein was able to lower SMC numbers in culture to a 
significant higher degree depending on the concentration applied. In comparison to other 
oestrogen-like structures (daidzein, equol, resveratrol), genistein had the biggest impact on 
lowering DNA synthesis rate in SMCs, when PPAR- γ receptor was blocked. 
 
Discussion 
 
The medical and economical relevance of atherosclerosis and CVD cannot be overrated. The 
high incidence in the western world, as well as the high mortality rate caused by heart attack 
underline the need of new and modern therapy concepts. After menopausal changes in the 
hormonal system – either by surgical intervention or by normal aging – the risk of CVD 
increases rapidly in femals. Hormone replacement therapy can protect the cardiovascular 
system from effects, associated with CVD and atherosclerosis. Until now it was believed, that 
oestrogen or estrogen like molecules mediate protective effects via the estrogen receptors 
(ER). Our studies show that certain effects of phytoestrogens on smooth muscle cells from the 
human aorta are not mediated via ERs but via PPAR- γ receptor. Even when ERs are 
completely blocked, cell proliferation parameters and collagen synthesis can be decreased 
following genistein treatment. Compared to different phytoestrogens, genistein has the most 
powerful impact and is therefore a promissing target drug for hormon replacement in this 
term. 
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Abbreviations 
 
HSP:  heat shock proteins 
ER:  oestrogen receptor 
ERE:  oestrogen response element 
AP-1:  activating protein 1 
SMC:   smooth-muscle cell 
vSMC: vascular smooth-muscle cell 
PE:  phytoestrogens 
CVD:  cardiovascular desease 
HDL:  high-density lipoprotein 
HEGF: human epidermal-growth-factor 
LDL:  low-density lipoprotein 
HRT:  hormon replacement therapy 
HSP:  heat shock proteins  
ERE:  oestrogen responsive elements 
PPAR-γ: peroxisome proliferator-activated receptors
MAPK: mitogen-activated-protein-kinase 
SHBG: sex-hormone-binding-globulin 
TCA:  trichloroacetic acid 
TZD:  thiazolidinediones 
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1. Introduction 
 
 
1.1. Nuclear receptor group and Peroxisome Proliferator Activated 
Receptors 
 
Nuclear receptors are one of the biggest groups of transcription factors, being activated 
through the binding of hydrophobic ligands. Within this family the group of Peroxisome 
Proliferator Activated Receptors (PPAR) contains three members: PPAR-α, PPAR-γ, and 
PPAR-δ. These receptors can be activated by both, synthetic and natural ligands such as 
eicosanoids, free fatty acids, lipid-lowering drugs and thiazolidinediones (TZDs).  
PPAR-α is expressed in liver, heart, kidney, muscle and adipose tissue. When activated, the 
expression of apolipoprotein in the liver is increased, which subsequently leads to an 
inhibition of lipoprotein lipase (LDL). In the development of atherosclerosis, PPAR-α 
mediated effects in endothelial cells and smooth muscle cells (SMCs) inhibit inflammatory 
responses. Several factors like NO-synthase, monocyte chemotactic protein 1 (MCP-1), 
interleukin-6 and others are downregulated following activation of PPAR-α.  
PPAR-γ, the second memeber of the PPAR family has three isoforms: PPAR-γ1, PPAR-γ2 
and PPAR-γ3. While isoforms 1 and 3 encode the same polypeptide, isoform 2 contains 
additional 28 amino acids. Type 2 is predominantly expressed in adipose tissue, whereas type 
3 is expressed in adipocytes and macrophages. Type 1 is widely expressed in all kinds of 
tissues. Fatty acids and eicosanoids are natural ligands for all isoformes – the TZDs are the 
best studied synthetic ligands. Activation of PPAR-γ by TZDs induces the expression of a set 
of genes involved in adipocyte differentiation and lipogenesis, and these effects are thought to 
be responsible for the insulin sensitizing action of these drugs. 
Compared to the other members, only litlle is known about PPAR-δ. It is expressed in brain, 
macrophages, lung, adipose tissue and muscle. The natural ligands are prostanoids. There are 
results suggesting an important role of PPAR-δ in regulation of energy ependiture as well as 
glucose and lipid metabolism. This highlights the potential use of PPAR-δ modulators as 
therapeutical agents for diabetes, obesity and atherosclerosis.  
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1.2. Phytoestrogens – chemical structure, nomenclature and sources 
 
Some naturally occuring compounds present in plants have been found to possess oestrogenic 
properties by binding to oestrogen receptors. This group of phenolic compounds, been termed 
phytoestrogens is divided into flavonoids and non-flavonoids. Flavonoids are subdevided into 
three classes: coumestans, phenylated flavonoids and isoflavons, possessing the most potent 
oestrogenic activity (Fig.1.1.1). They are low molecular weight hydrophobic compounds, and 
their watersolubility can be increased by conjugation to glucose, glucuronide or sulfate 
groups.  
Quantification and analysis of phytoestrogens in foodstuffs as well as in pharmacological and 
toxicological studies are dependent on precise and accurate analytical methods, particularly 
with regard to the presence of phytoestrogens in only parts per billion to parts per million 
concentrations in plants, solid and liquid foodstuff as well as in biological matrices such as 
plasma, serum, urine and faeces. To analyse and quantify phytoestrogens various techniques 
are used, such as high-perfomance liquid chromatography with ultraviolet detection (HPLC-
UV) [1-3], gas chromatography with mass spectrometric detection (GC-MS) [4-6] and liquid 
chromatography with mass spectrometric detection (LC-MS) [7, 8]. Recently Immunoessays, 
using polyclonal antibodies raised against genistein and others have been developed and are 
equally sensitive, but less time consuming and expensive then the techniques mentioned 
above [9]. 
 
 
 Phytoestrogens 
   
               Flavonoids           Non-Flavonoids 
Isoflavons     Coumestans     Prenylflavonoids    Lignans 
Genistein 
Daidzein 
(Equol) 
Glycitein 
Biochanin A 
Formononetin 
 
Coumestrol 
 
8-Prenylnaringenin 
6-Prenylnaringenin 
Xanthohumol 
Isoxanthohumol 
Lariciresinol 
Isolariciresinol 
Matairesinol 
Secoisolariciresinol 
(Enterodiol) 
(Enterolactone) 
Fig 1.2.1: The relationship between the various groups of phytoestrogens and members of each group. 
 
Natural sources 
 
Phytoestrogens are natural constituents of many plants, seeds and grains.There is considerable 
variation of phytoestrogen concentrations in different plants. A number of factors can 
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influence the phytoestrogen content including species, strain differences and environmental 
conditions [10]. Processing can also alter the phytoestrogen content of foodstuffs. The most 
prevalent dietary isoflavones include genistein, daidzein, and glycitein. These compounds are 
primarily found in legumes where they occur as glucoside, while fruits, vegetables, nuts and 
cereals are all minor sources of isoflavones [11]. Soybeans and soy-based foodstuffs are a 
particularly rich source of isoflavones, especially genistein and daidzein [12]. In general, 
commercial processing of soy into food products reduces phytoestrogen concentrations and 
can alter the chemical form of isoflavones present .  
Soybeans have played an integral part in some Eastern cultures (e.g. Japanese and Chinese) as 
a foodstuff for many centuries. Comparison of estimated dietary isoflavone intakes in Western 
and Eastern populations illustrate that Eastern populations have a significantly higher intake 
of phytoestrogens [13]. 
 
 
1.3. Absorption, distribution, metabolism and excretion of phytoestrogens 
 
Absorption 
 
In the natural source – food – phytoestrogens are mainly present as glucosides. Isoflavones 
are absorbed as aglucones, which are more readily absorbed than the parent glucosides due to 
their higher hydrophobicity and lower molecular weight. Glucosides of isoflavones themselfes 
have not been identified in plasma, showing that uptake requires hydrolysis of the isoflavone 
glucosides to their aglucone form [14], although there is debate whether aglucones are more 
bioavailable than the glucosides. There is evidence that the liver and enterocytes of the human 
small intestine contain ß-glucosidase enzymes capable of efficiently hydrolysing some, but 
not all, naturally occurring flavone and isoflavone glucosides [15]. Another study also 
suggested that isoflavone glucosides can be converted to aglucones by enzymes in saliva [16]. 
Richelle et al showed that plasma concentrations of isoflavones were similar in subjects after 
consumption of a soy drink which had been enzymatically treated to convert the isoflavone 
glucosides to their aglucone form, compared to subjects that had ingested the untreated drink 
[17].  
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Fig 1.3.1: Schematic representation of absorption of daidzein from the gut. 
Prior to absorption from the gut, daidzein is converted to daidzein by gut microfloral enzymes. It is partially 
converted to glucuronide and sulphate conjugates by enzymes in the liver before entering the peripheral 
circulation. These conjugates can be excreted back into the gut from the liver via the bile duct (enterohepatic 
circulation) where they can be deconjugated by gut microfloral enzymes. They may then be re-absorbed or 
further transformed in the gut and absorbed. 
 
 
Distribution and metabolism 
 
Once absorbed from the intestine, isoflavones are efficiently reconjugated, either with 
glucuronic acid or sulfate. Conjugation mainly takes place either in the liver (hepatic UDP-
glucuronosyl transferase or sulfotransferase enzymes) [12, 18], or directly in the intestinal 
epithelium, which has also been shown to posess glucuronosyl transferase and 
sulfotransferase activity [19]. Isoflavones are therefore present in the circulation in 
predominantly conjugated forms. 
Focussing on genistein, five metabolites were identified following an oral dose of 4 mg 
genistein/kg bw in a rat animal model. These metabolites were identified as genistein 
glucuronide, dihydrogenistein glucuronide, genistein sulphate, dihydro-genistein and 4-
hydroxyphenyl-2-propionic acid [20], indicating the further transformation of genistein after 
uptake.  
Isoflavones have been detected in a number of body fluids such as urine, plasma, faeces, 
prostatic fluid, semen, bile, saliva, breast milk, breast aspirate and cyst fluid. The major 
isoflavones and their metabolites detected in the blood and urine of humans and animals are 
daidzein, genistein, equol and O -DMA [18, 21]. Plasma and tissue concentrations of 
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genistein increased dose dependently. Genistein was predominantly (95-99%) present in the 
conjugated form in plasma but to a much less extent also in tissues. Gender differences in the 
tissue concentrations of genistein and the proportion of genistein in conjugated form were 
evident particularly in the liver, thyroid and mammary glands. Only very little genistein was 
detected in the brain [8]. The following figure shows the plasma and tissue concentration of 
genistein (Fig 1.3.2). 
Pharmacokinetically, plasma genistein concentrations had significantly increased 2 hours after 
ingestion and reached maximum concentrations 6 hours thereafter. In the same study, plasma 
concentrations of daidzein peaked at approximately the same time but was lower than 
genistein [22]. Most isoflavones were recovered in the faeces 2-3 days after ingestion. In a 
study of Setchell et al the mean plasma half-lives were 7.7 hours, while peak plasma 
concentrations again were greater for genistein than daidzein at the doses used, suggesting 
genistein is the more bioavailable isoflavone [23]. The extent of free phytoestrogen available 
for biological interaction in the plasma is determined by the extent to which they are bound to 
plasma proteins which renders them unavailable to interact with other molecules, such as 
oestrogen receptors (ERs). 
 
 
Fig. 1.3.2: Plasma and tissue concentrations of genistein in male and female rats. 
Concentrations and percentage unconjugated genistein shown are from animals (n=6) exposed to 500mg 
genistein/kg diet.Adapted from Chang et al. [8] 
 
Excretion 
 
Excretory routes for phytoestrogens are urine and bile. Several bacterial metabolites of 
isoflavones have been detected in urine and faeces. Maskarinec et al. compared intake and 
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excretion of different isoflavones and found that Chinese subjects, having an isoflavone intake 
of 38 mg/d excreted 307,6 mmol/h via urin, while Caucasian subjects with an daily intake of 
only 6,9 mg excreted 139 mmol/h [24]. The excretion of daidzein in rats was investigated 
after a single oral dose of 100 mg daidzein/kg bw [25].Total urinary excretion accounted for  
< 10% of the dose. Coldham et al. found, following an oral dose of 14 C-labeled genistein    
(4 mg/kg bw) to rats of both gender, that 66% and 33% of the dose was excreted in urine and 
faeces, respectively [26].  
 
 
1.4. Oestrogen action and receptor mechanism 
 
Oestrogens are hormons of the steroid family involved in various processes regulating 
development, growth and function in adults. They interact with numerous tissue types in both, 
males and females. They mainly act through ligand-activated nuclear transcription factors, 
known as oestrogen receptors (ERs). They – like other steroid hormone receptors – are 
members of the nuclear receptor family of transcription factors that exhibit common structural 
domains. If not complexed with heat shock proteins (hsp) in the cytoplasm waiting to be 
activated by a certain ligand, they are predominantly located in the nucleus. Activated dimers 
show a high binding affinity for specific DNA-binding sites called oestrogen receptor 
response elements (ERE), which are located in an upstream promotor position of oestrogen 
sensitive genes (Fig 1.3.1). Probably other proteins, generally refered to as coactivators or 
codepressors are essential for ER action influencing the level of expression of oestrogen-
related genes [27, 28]. The structure of EREs is a 13-base pair inverted repeat motif (2 
inverted repeats of AGGTCA or at minimally GGTCA) [29], facilitating the binding of ER 
units as a homodimer, while sequences flanking the ERE may also play a role in the binding 
process of ERs. At the same time an alternative way of oestrogen-related gene activation is 
discussed, using an ERE-independent pathway. ER then interacts with activating protein 1 
(AP-1) and with transcription factor Sp1, causing activation of respective responsive elements 
[30].  
The differential tissue distribution of ER and their variant subtypes may only partly explain 
the tissue specific effects of oestrogens. Tissue specificity may in fact be attributable to the 
nature of the dimers formed by receptors and their interaction with accessory proteins. 
Different groups have found that ERs are able to form certain heterodimers [31-33] that bind 
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directly to the ERE sequence. In consequence there are at least three possible pathways 
through which oestrogens may activate target genes by dimerisation. 
 
 
Fig. 1.4.1: Mechanism for the receptor mediated induction of oestrogen responsive genes. 
Oestrogen receptors can move between the nucleus and the cytoplasm, but under normal conditions they are 
predominantly located in the nucleus. Upon entering the cell, oestrogens bind to ERs which are complexed with 
heat shock proteins (hsp). Upon ligand binding (L), the hsps dissociate from the receptor, allowing two ERs to 
dimerise and bind to DNA containing the oestrogen responsive elements (ERE) found within genes responsive to 
oestrogen. Receptor and ERE binding promotes gene transcription and the synthesis of protein which produces 
an oestrogenic response such as cell proliferation (Adapted from Parker [29]). 
 
 
Oestrogen receptor subtypes 
 
To date, basically 3 different receptor subtypes are described [34-36]. The ER binds a large 
number of compounds that exhibit remarkably diverse structural features. In fact, the 
oestrogen receptor is probably unique among the steroid receptors in its ability to interact with 
a wide variety of compounds. This is also true for the ERα and ERß subtype. 
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ERα and ERß subtypes can interact with a wide variety of different compounds although 
some ligands appear to have different relative affinities for the different subtypes. Showing 
their very different origin in humans, the gene for ERα is located on chromosome 6 while the 
one for ERß is located on chromosome 14 [37]. Their very similar protein structure suggests 
that both receptors may interact with similar response elements. It is known, that ERα and 
ERß subtypes both, bind oestradiol and other ligands with similar affinity. On the other hand 
it has been proposed that both receptors act in an antagonistic way. ERß often appears to 
quench activities up-regulated by ERα , particularly in the context of cell proliferation which 
has been shown in in vitro cell transfection studies by Reynolds et al. [38].  
In addition, several authors described further subtypes of ERs, like ERβΔ5 [39], ERβx [40] 
and several subtypes of ERα [41-43], but their function is uncertain and needs further 
investigation. 
 
Tissue distribution of ERs 
 
It does not surprise that expression of ERα and ERß has been found in all major human 
uterine cell types at every menstrual stage, although variable expression profiles of the two 
receptor types occur within tissues of the developing human fetus. 
In rat and mouse, different regions and cell-populations in the brain, including the 
Hypothalamus and pituitary gland appear to express either ERα or ERß exclusively, although 
one minor cell population within the rat pituitary co-expresses both receptors. The different 
cell types within the rat ovary have also been found to exhibit differences in receptor 
expression and these may be influenced by the stage of development or maturation of the 
animal. A list of tissues expressing either both or at least one receptor type is given in figure 
1.4.3, showing the complex expression pattern of these two receptors, as well as the different 
distribution between rodents and humans. 
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Fig. 1.4.3: Tissue distribution of ER subtypes in humans and rodents. 
 
Binding of phytoestrogens to ERs 
 
Fitting very well to the binding site of ER which interacts directly with the ligand and 
determins its affinity for the receptor, oestradiol shows a high affinity. Because of the flexible 
character of the binding site of ER and its ability to accomodate a wide range of compounds 
with structural similarities it was shown that phytoestrogens also bind to these [44-47]. Their 
affinity for ERs is defined by their biochemical structure (Fig. 1.4.4).  
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Fig. 1.4.4: The selectivity of oestradiol and phytoestrogen binding to ERα and ERß 
The table shows the binding affinities of phytoestrogens to each receptor subtype relative to the binding affinity 
of oestradiol (arbitrarily set at 100). (a) as referred to Kuiper et al [48]; (b) as reffered to Milligan et al [49] 
 
The ringarrangement and the presence and position of chemical groups such as hydroxyl 
groups [50, 51] play important roles in the structural compatibility. Genistein for example 
binds to both ERs, which can be explained by the similar size to oestradiol and has hydroxyl 
groups which are appropriately positioned to fit in the binding pockets (Fig. 1.3.5-1.3.7) [44, 
45].  
 
 
Fig 1.4.5: Beta-Oestradiol 
 
 
Fig 1.4.6: Genistein 
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Fig. 1.4.7: Oestradiol and genistein binding to the ligand-binding domain of the oestrogen receptor. 
The figure shows selected interactions (marked with arrows) between oestradiol (A) and genistein (B) and 
specific amino acids in the ligand-binding pocket of ERß. 
 
Binding to ERs, phytoestrogens may act in an activating or blocking way. If phytoestrogens 
bind to and activate the receptor – similar to oestradiol – this is referred to as agonist activity 
[52]. If it binds to the ER, but blocks further biological response, it is referred to as 
antagonist. If phytoestrogens are able to induce a biological response at levels comparable to 
these of oestradiol they are called potent agonists, in spite of those, which require much 
higher concentrations to cause a biological response and are deemed weak agonists. 
 
The same is true for antagonists. Some phytoestrogens are very weak agonists and by 
blocking the oestrogen receptor for binding of more powerful ligands they have antagonist 
activity. These compounds are known as partial agonists [53, 54].  
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It was also predicted that the receptor-bound ligand is completely surrounded by the receptor 
with minimal exposure to solvent [44]. 
 
 
 
 E E
ER
ER-
mRN
E 
ER-
E
ER-
Ligand
Effector 
Molecul
SMC Growth 
Inhibition 
Relaxation 
Anti-vasoocclusive 
Cardioprotective 
Actions 
nucleus 
cell 
Fig 1.4.8: Biological Effects of Estradiol: the Conventional Mechanism 
 
Apart from the regular ligand-dependent way of activation (Fig. 1.3.8), there is a ligand-
independent way by phosphorylation, caused by human epidermal-growth-factor (HEGF), 
receptor HER2 and insulin. Using the Ras-signal-transduction pathway and the mitogen-
activated-protein-kinase (MAPK), they are capable of activating the transcription of ERs-
related genes.  
 
Once bound by oestrogens, the ER undergoes a conformational change allowing the receptor 
to interact with chromatin and to modulate transcription of target genes [55-57]. 
 
 
1.5. Effects mediated by phytoestrogens 
 
Indirect effects of phytoestrogens 
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Like oestradiol and testosterone, phytoestrogens are circulating bound to sex-hormone-
binding-globulin (SHBG). In adult women, nearly all oestradiol is associated, either to SHBG 
(37%), or to serum albumin (61%), while only unbound hormon can be taken up into cells and 
bind to ERs and there elicit biological effects. Interestingly also testosterone is associated 
with binding proteins to nearly 100%, 40% is bound to SHBG.  
By binding to SHBG, phytoestrogens inhibit binding of oestrogens (and testosterons) to 
increase the plasma concentration of their unbound form. Although Nagel et al. [58] were able 
to show that isoflavones bind to SHBG with a 1000-5000-fold lower affinity than oestradiol, 
this effect may play a certain role. At the same time it has been suggested that phytoestrogens 
stimulate the synthesis of SHBG and thereby reduce the concentrations of free hormone-
levels in the circulation plasma.  
 
Clinical effects 
 
Clinical effects of phytoestrogens are very complex and invole completely different organ 
systems. It would be very extensive to introduce all known effects of phytoestrogens, 
especially because they affect dozens of different specialities in the clinical environment. The 
following enumeration gives an overview of the systems, involved in phytoestrogen effects: 
 
1. fertility and development 
2. thyroid gland and thyroid function 
3. central nervous and immune systems 
4. osteoporosis 
5. cancer 
6. cardiovascular system 
 
1. fertility and development 
Testosterone produced by the fetal testes is mandatory for normal sexual development of the 
male child. Development of the female is not hormone dependent. Exposure of the male and 
female fetus to oestrogens or androgens disturbs normal sexual differentiation, although 
potential effects are different in the male and female. Studies on the effects of phytoestrogens 
on development and fertility are limited in number and scope [59-62]. In utero effects of 
phytoestrogens are not published for human studies. It is extremely difficult to examine these 
potential effects on human development and reproduction for both, practical and ethical 
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reasons. Hence most of the published research has been conducted in laboratory animals. 
Experiments in rodents suggest that genistein produces oestrogenic effects in both, male and 
female rodents but effects may be of more impact in the female rodent [59-62]. Exposure 
during the perinatal, neonatal or prepubertal stages of development produce the most marked 
effects. The significance of these effects such as alterations in sex hormone concentrations, 
advancement of vaginal opening, mammary gland development, irregular oestrus cyclicity 
and abnormal histology of the reproductive tract to humans is unclear. 
 
2. thyroid gland and thyroid function 
Experimental data suggest that high levels of phytoestrogens may have a goitrogenic effect in 
rodents deficient in dietary iodine. Data from human studies suggest that dietary soy or 
isoflavones are unlikely to affect thyroid function in normal individuals with adequate iodine 
intake. In children it may be possible, that the isoflavone component of soy-based infant 
formula may interfere with the thyroid function [63-65].  
 
3. central nervous and immune systems 
In humans, the blood brain barrier is not fully developed at birth and for this reason the CNS 
may be more accessible to phytoestrogens in utero or at birth. However, few studies have 
examined the transfer of phytoestrogens from the peripheral blood to the CNS. The published 
data indicates that transfer across the blood brain barrier in rodents is relatively inefficient (at 
least in adults), as concentrations of isoflavones in the CNS are several orders of magnitude 
lower than in peripheral blood [66]. 
A small number of studies have examined the transfer of phytoestrogens from the peripheral 
blood to the CNS in rodents, where they possibly may influence behaviour, movement, 
cognition, pain sensitivity and protect against development of neurodegenerative diseases. 
Exposure to isoflavones (>200 mg/kg diet) can cause low concentrations of proteins in the 
CNS, although these effects are not shown by representative studies [66]. 
In terms of influencing the immune function, oestradiol is known to affect the development 
and organisation of lymphoid tissues and the activity of various cellular vectors of immune 
function. It is therefore cogitable that phytoestrogens have comparable effects, because there 
is evidence that oestrogen receptor activation (also caused by phytoestrogens) can influence 
lymphoid development [67-70].  
Genistein has been shown to inhibit human T-cell proliferation, interleukin production and IL-
2 receptor expression in vitro [67]. 
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4. osteoporosis 
Numerous studies have shown, that phytoestrogens have a beneficial role in preventing bone 
loss following ovariectomy and that they are effective in conserving bone in rodent models of 
osteoporosis [71-77]. Even in humans, epidemiological studies suggest that intakes of 
phytoestrogens are associated with higher bone mineral density in populations consuming 
relatively large amounts of soy. There is a paucity of long-term studies in humans 
investigating phytoestrogen levels in relation to changes in bone mass. Big long-term studies 
in humans would be required before the efficacy of phytoestrogen-containing foods or 
supplements can be confirmed. 
 
5. cancer 
It is known that lifetime exposure to oestrogen is related to high risks of developing breast 
cancer [16]. It was suggested that exposure to oestrogen during development or early life may 
also play an important role in programming hormonal homeostasis and may influence the risk 
of developing cancer later in life. The epidemiological (limited) evidence suggests a 
protective role for soy-based food in developing endometrial cancer. Studies looking at 
phytoestrogens in this context are still pending.  
There is no evidence from human studies to attribute the protective effect of fibre, fruit and 
vegetables against colorectal [78] and stomach cancer [79] to their phytoestrogen content. In 
addition, there is also little or no evidence to associate phytoestrogen application with a 
reduced risk of cancer of the ovary, prostate [80] or lung. 
 
6. cardiovascular system 
The structural similarity of phytoestrogens to oestrogens, which have hypocholesterolaemic 
effects, and the lower cardiovascular disease mortality rates in populations consuming soy 
have prompted the suggestion that phytoestrogens are protective against cardiovascular 
disease [12, 59, 81]. There is evidence from epidemiological studies and intervention trials 
that diets containing soy or soy protein isolates can have a hypocholesterolaemic effect in 
humans. Human studies have shown dietary soy has no effect on thrombosis. Only one human 
study suggests that dietary phytoestrogens may have a beneficial effect on one parameter of 
atherosclerosis [82].  
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2. General hypothesis and objectives 
 
Phytoestrogens are plant derived phenolic molecules that structurally resemble estrogens. On 
the basis of its chemical similarity to estradiol the overwhelming view has been that 
phytoestrogens may mediate its biological actions via estrogen receptors. This notion is 
further supported by the fact that phytoestrogens bind to both estrogen receptors α and β, as 
well as the fact that phytoestrogens like genistein mimic the antimitogenic actions of estradiol 
on SMC growth.  Although these findings suggest that phytoestrogens may mimic the effects 
of estradiol via ERs, however, recent findings from our group provide evidence that the 
antimitogenic effects of estradiol, but not genistein are blocked the ER antagonist ICI182780. 
This led us to hypothesize that the antimitigenic effects of phytoestrogens are mediated via an 
alternative pathway which does not involve ERs. Because, phytoestrogens have been shown 
to bind to PPAR receptor, together with the fact that drugs/ligands of PPAR inhibit SMC 
growth and are vasoprotective, we hypothesize that the antimitogenic actions of 
phytoestrogens may potentially be mediated via PPAR- γ.  In the present study using ER and 
PPAR antagonists we tested our hypothesis. 
 
 
3. Material and Methods 
 
3.1. Human Aortic Smooth Muscle Cell Culture (HASMCs) 
 
Human SMCs from adult thoracic aortas (Cascade Biologics, Inc.) were cultured under 
standard tissue culture conditions (37°C, 5% CO2) in M231 (Cascade Biologics, Inc, USA) 
culture medium supplemented with smooth muscle growth supplement (containing 5% v/v 
FBS, human fibrobast growth factor, human epidermal growth factor and insulin) and  
antibiotics-antimycotic substances (100 μg/ml streptomycin, 100 μg/ml penicillin and 0.025 
μg/ml amphotericin B, Gibco BRL, Paisley, UK). Medium was changed every 2 days and 
when cells reached subconfluency they were washed twice with HBSS (without Ca²+ and 
Mg²+,Bioconcept, Allschwil, CH) and trypsinized in 0.025% v/v Trypsin (Sigma, St. Louis, 
USA). HASMCs in the third through sixth passages were used for all experiments. 
 
 
3.2. Cryopreservation of Cells 
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Subconfluent cells were trypsinized in 0.025% v/v Trypsin and centrifuged 10 min, 1200 rpm 
at RT. The pellet was resuspended in ice-cold culture medium (2ml/75 cm² flask) containing 
7.5% DMSO (Fluka, Buchs, CH) as cryoprotective agent. Aliquots of 500 μl were gradually 
frozen to –70°C in cryotubes in a Mr. Frosty box. For long-term storage the cells were kept in 
liquid nitrogen. 
 
 
3.3. Cell Thawing 
 
The cryotubes containing the frozen cells were rapidly thawn under warm water. The content 
was transferred to a tube and 14 ml of fresh growth medium were slowly added. The cells 
were then plated in 75 cm² culture flasks (Gibco BRL, Paisley, UK) and incubated under 
standard tissue culture conditions. 
 
 
3.4. DNA Synthesis 
 
H-thymidine (specific activity 11.8 Ci/mmol, ICN Biomedicals) incorporation and cell 
number studies were conducted to investigate the effects of phytoestrogens on mitogen-
induced DNA synthesis and cell proliferation, respectively.  
HASMCs were plated in 24 well tissue culture dishes (1x104 cells/well) and allowed to grow 
subconfluence in DMEM/F12 (phenol-red free, Gibco BRL, Paisley, UK) containing 10% 
fetal calf serum (steroid free and delipidated, Gibco BRL, Paisley, UK) under standard tissue 
culture conditions. The cells were then growth-arrested by feeding DMEM (phenol red free) 
containing 0.4% albumin for 48 hours. For DNA synthesis, growth was initiated by treating 
growth arrested cells for 20 hours with DMEM containing 2.5% FCS (fetal calf serum) and 
containing or lacking genistein (Sigma Chemicals, St. Louis, USA) or rosiglitazone or various 
phytoestrogens (daidzein, equol, resveratrol) with or without the oestrogen receptor antagonist 
ICI 182,780 (in all experiments 2 μmol/l, Tocris, Bristol, UK) and PPAR-γ antagonist GW 
9662 (in all experiments 2 μmol/l, Sigma). After 20 hours of incubation the treatments were 
repeated with freshly prepared solutions but supplemented with H-thymidine for an additional 
4 hours. The experiments were terminated by washing the cells twice with Dulbecco’s 
phosphate buffered saline and twice with ice-cold trichloroacetic acid (10%). The precipitate 
- 22 - 
Role of PPAR-ϒ and ER in mediating the anti-mitogenic actions of phytoestrogens 
 
was solubilized in 500 μl of 0.3 N NaOH and 0.1% sodium dodecylsulfate (Sigma Chemicals, 
St. Louis, USA) after incubation at 50°C for 2 hours. Aliquots from 4 wells for each treatment 
with 10 ml scintillation fluid were counted in a liquid scintillation counter.  
 
 
3.5. Collagen Synthesis 
 
Confluent monolayers of HASMCs growth arrested for 48 hrs were treated in 24-well plates 
for 36 hrs with DMEM supplemented with 2.5% FCS plus L-[³H]praline (1 µCi/ml) in the 
presence or absence of the test agents. Following treatment, the experiment was terminated by 
washing the cells twice with PBS and twice with ice-cold 10% TCA. The precipitate was 
solubilized in 500 µl of 0.3 N NaOH and 0.1% SDS (50°C for 2 hrs). The samples were 
subsequently neutralized with 100 µl 5N HCL and aliquots from 4 wells for each treatment 
were counted in a liquid scintillation counter. To ensure that the inhibitory effects of the 
experimental agents on collagen synthesis were not due to changes in cell number, the 
experiments were conducted in confluent monolayers of cells in which changes in cell number 
were precluded. Additionally, cell counting was performed in cells treated in parallel with the 
cells used for the collagen synthesis studies, and the data were normalized to cell number. 
 
 
3.6. Cell number 
 
HASMCs were plated in 24 well plates (5x103 cells/well) and allowed to attach overnight. 
Cells were growth arrested as described above in DNS synthesis for 48 hours and 
subsequently treated every 24 hours for 4 days. On day 5 the cells were harvested by 
trypsinization and counted in a Coulter Counter.  
 
 
3.7. Statistical Analysis 
 
Data was analyzed with StatView using ANOVA and statistical significance (p<0.05) was 
calculated using Fisher’s Least Significant Difference Test. A value of p<0.05 was considered 
to be statistically significant.  
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4. Results 
 
 
All figures are based on mean values and standard deviation of three separate measurements. 
A value of p<0.05 was considered to be statistically significant. As described above all 
experiments were performed on human smooth muscle cells (HSMCs) under standard 
conditions. All values are compared to values of untreated SMCs which served as control. 
 
 
4.1. Effects of genistein on DNA synthesis 
 
To describe the effects of genistein on DNA synthesis, cell cultures of HSMCs were treated 
with genistein in different concentrations. DNA synthesis was measured as percentage of 
DNA synthesis rate of untreated cell cultures of HSMCs which served as control (data not 
shown).  
If  PPAR-γ receptor was blocked using GW9662 receptor blocker, DNA synthesis remains 
stable on levels around 100% compared to control (bright line, figure 4.1.1). 
Unblocked cells show a drop of DNA synthesis even treated with low levels of genistein. 
With increasing levels of genistein the DNA synthesis decreases continiously to levels around 
25% treated with a maximum concentration of 100 μmol/L genistein (darkline, figure 4.1.1). 
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Figure 4.1.1: DNA synthesis; * p<0,01 
 
Figure 4.1.2 shows DNA synthesis rates of SMCs treated with ER-blocker ICI18280 (bright 
line, figure 4.1.2.) compared to cells with normal ER-status (dark line, figure 4.1.2). 
Both lines show a decrease of DNA synthesis depending on different levels of genistein. DNA 
synthesis decreases with increasing levels of genistein to a minimum of around 25% in cells 
treated with a maximum of 100 μmol/L genistein not dependent on ER blocker ICI182780. 
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Figure 4.1.2: DNA synthesis 
 
 
4.2. Effects of genistein on collagen synthesis 
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To determin the effects of different genistein levels on collagen synthesis SMCs were either 
treated with PPAR-γ receptor blocker GW9662 or left unblocked. Unblocked cells showed 
decreasing collagen synthesis depending on increasing levels of genistein to a minimum of 
around 25% collagen synthesis at a maximum level of 100 μmol/L genistein. 
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Figure 4.2.1: Collagen synthesis; *p<0,01 
 
Figure 4.2.2 shows SMCs either blocked with ER blocker ICI182780 or left unblocked. Both 
lines show a decrease of DNA synthesis depending on different levels of genistein. DNA 
synthesis decreases with increasing levels of genistein to a minimum of around 25% in cells 
treated with a maximum of 100 μmol/L genistein independent from treatment with ER 
blocker ICI182780. 
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Figure 4.2.2: Collagen synthesis 
 
 
4.3. Effects of genistein on SMC proliferation  
 
To investigate the effects of different genistein levels on cell numbers SMCs were again 
treated with PPAR-γ receptor blocker GW9662 or left unblocked. Unblocked cells showed 
decreased cell numbers depending on increasing levels of genistein treatment to a minimum 
of around 25% at a maximum level of 100 μmol/L genistein. 
 
 
Figure 4.3.1: Cell number; *p<0,01 
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Both, ER-blocked SMCs and unblocked SMCs showed decreasing cell numbers depending on 
different levels of genistein. The cell number decreases with increasing levels of genistein to a 
minimum of around 25% in cells treated with a maximum of 100 μmol/L genistein not 
dependent on treatment with ER blocker ICI182780. 
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Figure 4.3.2: Cell number 
 
 
4.4. The effect of Rosiglitazone and Genistein on SMC growth via PPAR-γ  
 
To show the effects of the best studied PPAR-γ agonist Rosiglitazone [83] on cell numbers 
SMCs were again blocked with PPAR-γ receptor blocker GW9662 or left unblocked. 
Unblocked cells did not show a significant decrease of cell numbers even under increasing 
levels of Rosiglitazone up to 100 μmol/L. Blocked SMCs instead show a significant decrease 
of cell numbers to a minimum of around 60% depending on the increase of Rosiglitazone 
levels to a maximum of 100 μmol/L. 
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Figure 4.4.1: Cell number; *p<0,01 
 
Comparing the effects of Rosiglitazone and genistein on cell numbers Rosiglitazone in a dose 
of 100 μmol/L leads to a decrease of cell numbers to a minimum of around 60%. 
A treatment with 100 μmol/L genistein lowered the cell number to levels around 25%. Notice 
the drop of cell numbers in the genistein treatment when dose is raised from 10 to 50 μmol/L. 
If genistein dose is again raised from 50 to 100 μmol/L cell numbers nearly remain stable at 
levels of 25%. 
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Figure 4.4.2: Cell number; *p<0,01 
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4.5. Antiproliferative Actions of Estradiol, Rosiglitazone and 
phytoestrogens 
 
Looking at the effects of treatment with estradiol, rosiglitazone and genistein (each 10 μmol/l 
in all experiments) on cell numbers in SMCs either blocked with GW9662 or not, oestradiol 
had the lowest effect on cell numbers independent from treatment with PPAR-γ receptor 
blocker GW9662.  
Measured four days after treatment rosiglitazone shows the most significant effect with a cell 
number of around 75% in unblocked and around 97% in blocked SMCs.  
Compared to rosiglitazone, genistein treatment lead to cell numbers of around 62% in 
unblocked and around 90% in blocked cells.  
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Figure 4.5.1: Cell number; *p<0,01 (compared to control) 
 
To demonstrate the effects of different phytoestrogens on DNA synthesis, receptor blocker 
GW9662 was again used to block PPAR-γ-receptor in SMCs. Measurements were performed 
four days after treatment. While DNA synthesis in control group remained 100% in blocked 
and unblocked cells, it decreased under treatment of different phytoestrogens whether SMCs 
were blocked or not. Apart from cells treated with Equol, DNA-synthesis droped to higher 
extent when PPAR-γ receptor was left unblocked. Treated with Equol, DNA synthesis 
remained stable at a level of 80% compared to control in both, blocked and unblocked cells. 
Genistein treatment of cells with unblocked PPAR-γ-receptor showed the highest level of 
decrease with a value of 40% compared to control.  
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In general, a phytoestrogen treatment induced a decrease of DNA synthesis in SMCs to a 
level of around 60% (compared to control), while an aditional treatment with PPAR-γ-
receptor blocker GW9662 lowered the DNA synthesis rate to levels of around 80%. 
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Figure 4.5.2: DNA Synthesis; *p<0,05; **p<0,01 
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5. Discussion 
 
 
5.1. Clinical backround 
 
Most Western countries face high and increasing rates of cardiovascular disease. Each year, 
heart disease kills more people than cancer. Diseases of the heart alone account for 30% of all 
deaths, with other diseases of the cardiovascular system causing substantial further death and 
disability. It is the number one cause of death and disability in the United States and most 
European countries. Studies showed vascular injury accumulates from adolescence, making 
primary prevention efforts necessary prior to its initiation. By the time the heart problems are 
detected, the underlying cause (atherosclerosis) is usually quite advanced, having progressed 
for decades. There is therefore increased emphasis on preventing atherosclerosis by 
modifying risk factors, such as healthy eating, exercise and avoidance of smoking. 
Cardiovascular disease (CVD) has a very high incidence in both, man and woman [84-87]. 
Relevant factors for the genesis of CVD are diabetes mellitus, high blood presure, high levels 
of lipoproteins (low-density lipoproteins, LDL) and adipositas, smoking and age – to name 
some known causes (Fig. 5.1.1) [88-92]. CVD can cause severe effects to the human body 
like cerebral insults or heart attacks. It further causes peripheral atherosclerosis which can 
lead to surgical intervention or even limb amputation. This makes CVD to a major desease in 
the western world, a major cause of death and a significant financial factor in the national 
health system [93, 94]. The pathogenesis of atherosclerosis is based on the development of 
changes in the vascular system. High amounts of LDL stick to sights of damage at the vessel 
wall structure, causing what is called plaques. These plaques lower the diameter of the vessel 
and therefore the blood flow through the constriction, leading to a decreased blood supply in 
the periphery. Proliferation of SMCs from the vessel wall and recruitment of inflammatory 
cells to these sights of plaque-formation can then produce vasoocclusive diameters by 
interacting with thrombocytes and other inflammatory cells. This acute incident can cause a 
complete blood flow breakdown situation such as cerebral or coronary arteries – a heart attack 
or cerebral insult occurs. 
Interestingly, although CVD is the number one cause of death for individuals in modern 
society, a majority of young people are unconcerned about the risk for development of this 
disease. Atherosclerosis is a process that develops over decades and is often silent until an 
acute event (heart attack) develops in later life. Intimal lesions appear in all the aortas and 
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more than half of the right coronary arteries of youths aged 15–19 years. However, most 
adolescents are more concerned about other risks such as HIV, accidents, and cancer than 
cardiovascular disease. This is extremely important considering that 1 in 3 people will die 
from complications attributable to atherosclerosis. 
 
• Modifiable Risk Factors  
o Tobacco smoking  
o Insulin resistance & Diabetes mellitus  
o Hypercholesterolemia (elevated cholesterol levels) and abnormal 
lipoprotein particle profile (cholesterol subtypes)  
o Obesity, especially central or male-type obesity; apart from being linked to 
diabetes, this form of obesity independently increases cardiovascular risk, 
presumedly by inducing an inflammatory and procoagulant state  
o High blood pressure  
o Elevated heart rate[4]  
o Physical inactivity/Sedentary lifestyle  
o Absence of key nutritional elements, such as omega-3 fatty acids and 
polyphenol antioxidants  
o Exposure to high levels of environmental noise  
o Stress  
o Depression  
o Periodontal disease  
• Non-modifiable Risk Factors  
o Age  
o Gender, men under age 64 are much more likely to die of coronary heart 
disease than women, although the gender difference declines with age. [2] 
(The gender difference is less pronounced in blacks than in whites, but it is 
still significant [3])  
o Genetic factors/Family history of cardiovascular disease  
Fig. 5.1.1 risk factors which associate with (but are not all causes of) various forms of cardiovascular disease 
 
It is well known, that – compared to man of the same age – women younger than 45 years are 
somehow “more protected” against CVD [95]. After menopausal changes in the hormonal 
system – either by surgical intervention or by normal aging – the risk of CVD increases 
rapidly in femals [96-100]. This is caused by a shift of the lipidprotein profile from protective 
high-density lipoproteins (HDL) to low-density lipoproteins (LDL), which is a major cause of 
atherosclerosis and therefore CVD. LDL receptor numbers decrease which leads to a low 
level of LDL katabolism [101]. It is well known, that oestrogen replacement therapy (HRT) 
can protect the cardiovascular system from these effects [102-105]. Some animal models 
show that further effects of oestrogens help to lower the risk of CVD: Both, blood vessels and 
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heart endothelia can express oestrogen receptors and thereby influence vessel tonus and cell-
adhesion to the vessel wall which are important factors for the development of plaques 
causing atherosclerosis [106]. Studies show a decreased risk for CVD of 50% in female 
patients with HRT [104, 107] while other studies discuss these effects controversly. One 
major problem is the fact, that apart from animal experiments showing cardioprotective 
effects of oestrogens, these results are not acknowledged by some other big studies [108]. The 
use of different types of oestrogens in studies could possibly explain the different results.  
Apart from the effects to the cardiovascular system there are severe side-effects of HRT such 
as increased risk for breastcancer, thrombosis and strokes beside many more [109]. It is 
therefore very important to find a treatment for postmenopausal women which provides a 
good cardioprotective effect and does not cause the unwanted side-effects of oestrogen. A 
possible target drug in this struggle are phytoestrogens such as genistein and others [110]. 
Different studies show good cardiovascular-protective effects [81, 110-119]. 
 
 
5.2. Effects via PPAR-γ receptor  
 
Although phytoestrogens are molecules not produced by the human body itself, different 
studies showed a binding to both, circulating globulins and oestrogen receptors [44-47]. 
Because of this very similar chemical structure and the binding to oestrogen specific sights it 
seems only logic that oestrogen receptors are the main mediators of effects caused by 
phytoestrogens. Our in vitro experiments show for the first time that blocking of oestrogen 
receptors does not lower certain effects of genistein. This means that phytoestrogens must 
bind to some other receptor and mediate their effect not only via oestrogen receptors. 
Focussing on certain pathways which are relevant for potential antiartherosclerotic effects of 
phytoestrogens, our experiments describe SMC proliferation parameters and collagen-
synthesis parameters.  
 
The role of cell proliferation on atherosclerosis with respect to our results 
 
Plaques, the morphologic visible form of atherosclerosis consist of different fractions. Main 
“building modules” of these intravasal cloggings are circulating cells and cells from the vessel 
wall to where the plaques are attached. Growing in the intima layer of the vessel wall smooth 
muscle cells proliferate into the plaques and thereby serve as material for plaque-growing 
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processes. A low level of cell proliferation in terms of low mitosis rate of these SMCs would 
lead to a decreased rate of plaques-formation and would therefore protect the vessel against 
atherosclerosis – one important cause of CVD. This is why we measured the proliferation rate 
of SMCs under the influence of genistein. 
Analyzing our results from measurements of cell numbers and DNA synthesis – both factors 
indicating the rate of cell proliferation – one can see that genistein can lower DNA synthesis 
rates and cell numbers in SMC culture with increasing levels of genistein (Fig. 4.1.1 and 
4.3.1, each p<0,01). Around a level of 10-50 μmol/l genistein, cell numbers and DNA 
synthesis rates drop down, indicating an optimal dosage in this concentration range. If PPAR-
γ receptor is now blocked by inhibiting effects of GW9662, DNA synthesis and cell number 
are stable suggesting that the antimitogenic effects are mediated via PPAR-γ receptor only.  
If oestrogen receptors are blocked as done in seperate experiments, the effects of genistein on 
cell number and DNA synthesis are not altered. There is no significant difference in the 
decrease of cell numbers and DNA synthesis under blocked ER showing that these effects are 
certainly not only mediated via the ER receptor pathway. 
Summarising it was shown that the effects of genistein on cell proliferation and DNA 
synthesis are mediated via PPAR-γ receptor and not only via ER. Concerning the dosage of 
genistein the optimal amount has to be discussed. In drug treatments the optimal dose 
describes the maximum of wanted effects causing a relative minimum of unwanted effects. 
From these results the optimal dose would be between 10-50 μmol/l. In our data we can find a 
“drop-zone” between these dosages. Our results aknowledge the already known protective 
effects of genistein on atherosclerosis. They show that these effects are not mediated via ER 
but via PPAR-γ receptor only. 
 
The role of collagen synthesis on atherosclerosis with respect to our results 
 
Another important factor are proteins expressed by plaques-forming cells such as SMCs. The 
most important extracellular protein for stable matrices is collagen. The chains can form 
stable networks of fibres leading to a rigid and lasting mass (plaques), which can cause vessel 
tightening as seen in the process of atherosclerosis. Because of this fact, we analyzed the 
amount of collagen synthesis by SMCs under the influence of genistein. 
If ER is left unblocked, genistein can lower the level of collagen synthesis in SMCs to a level 
of 25% as seen in figure 4.2.2. The effect of genistein is not influenced if ERs are blocked 
indicating an effect not depending on ERs. Genistein works in a dose-dependent manner, but 
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– again – shows a relevant drop of collagen synthesis levels in a dose of 10-50 μmol/l as seen 
before.  
Focussing on figure 4.2.1 where PPAR-γ receptors of SMCs were blocked one can clearly see 
that the effect on collagen synthesis disappears when PPAR-γ receptors are blocked. This 
proofs, that collagen synthesis, too, depends on the presence of unblocked PPAR-γ receptors 
but is not dependent on the presence of oestrogen receptors. Most effective levels of genistein 
are comparable to the other results with an optimal dose of 10-50 μmol/l. 
 
Rosiglitazone and genistein – same efficiency?  
 
Rosiglitazone (Fig. 5.2.1) is an oral drug that reduces the amount of sugar in the blood. It is 
used for treating patients with type 2 diabetes and belongs to a class of anti-diabetic drugs 
called thiazolidinediones. Member of this class is also pioglitazone. They are marketed by 
another pharmaceutical company, both as a standalone preparation and in combination with 
medication from the metformin-family. Rosiglitazone often is referred to as an "insulin 
sensitizer" because it attaches to the insulin receptors on cells throughout the body and causes 
the cells to become more sensitive (more responsive) to insulin and remove more glucose 
from the blood. At least some insulin must be produced by the pancreas in order for 
rosiglitazone to work. Rosiglitazone was approved by the FDA in 1999. Like other 
thiazolidinediones, its mechanism of action is by activating the intracellular receptor class of 
peroxisome proliferator-activated receptors, specifically PPAR-γ. Rosiglitazone is a pure 
ligand of PPARγ, and has no PPARα-binding action. 
In our experiments we evaluated the effect of rosiglitazone on cell numbers (anti-proliferative 
effect) and compared the efficiency to genistein. If SMCs are treated with rosiglitazone cell 
numbers decrease in a dose dependant manner to a level of 60%. If PPAR-γ receptors are 
blocked, cell numbers remain stable at levels around 100%, confirming that rosiglitazone 
mediates its effects via this receptor.  
If SMCs of the same source are treated with genistein and rosiglitazone and cell numbers are 
measured, both treatments lead to decreased cell numbers. As mentioned above rosiglitazone 
can lower cell numbers of SMCs to a level of 60%. Under genistein treatment using the same 
concentration the numbers of SMCs decrease to levels of around 25%. This proofs that both 
drugs can minish the rate of cell proliferation, but genistein has a much more powerful effect 
in our experiments. In genistein treatment we again find the drop in cell numbers in levels of 
10-50 μmol/l genistein, while rosiglitazone shows a stable decrement of cell numbers with 
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increasing dosages. Summarizing we were able to show, that both, genistein and rosiglitazone 
mediate their anti-prolifeative-effects via PPAR-γ receptors. The effects of genistein-
treatments are superior to the effects of rosiglitazone-treatments. 
 
 
Fig. 5.2.1 chemical structure of Rosiglitazone 
 
Estradiol, rosiglitazone and phytoestrogens  
 
One additional experiment was performed to proof, whether differences in the 
antiproliferative effects of different PPAR-γ receptor ligands can be quantified or not. For this 
purpose SMC cultures were treated with estradiol, rosiglitazone and genistein. Cell numbers 
were measured as percentage compared to a SMC culture without any treatment. Drug levels 
were equal throughout all treatments with 50 μmol/l. While untreated cell numbers stayed 
stable with (defining) 100%, SMCs treated with estradiol, rosiglitazone and genistein showed 
decreased cell numbers in all measurements. Estradiol is the most effective anti-proliferative 
drug, while genistein and rosiglitazone have comparable effects (Fig. 4.5.1). While blocking 
of PPAR-γ receptors does not have any additional effect in SMCs treated with estradiol, it 
certainly has in cells treated with rosiglitazone and genistein. This proofs, that the 
antiproliferative effects are mainly mediated via PPAR-γ receptor-dependent pathways. Our 
results further demonstrate, that genistein – although not as powerful as estradiol – is superior 
to rosiglitazone by the means of anti-proliferative effects. 
Measuring the DNA-synthesis rate in SMC cultures, cells were treated with different 
phytoestrogens (same dosage of 50 μmol/l) to compare the effects with blocked and 
unblocked PPAR-γ receptors. Our results demonstrate that daidzein, resveratrol and genistein 
work via PPAR-γ receptors: if these receptors are blocked, they show no significant effect on 
DNA-synthesis. Under unblocked condition genistein again has the most significant effect, 
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lowering DNA synthesis rates to levels of 40% compared to control. This again demonstrates 
the powerful efficiency of this drug (Fig. 4.5.2). 
 
The “perfect” target drug 
 
From the results shown above some properties of the target drug in the struggle to fight 
atherosclerosis can be characterized. The drug needs to slow down up-regulated SMC 
proliferation into the plaques and decrease the rate of collagen synthesis. We were able to 
demonstrate, that genistein has a dose-dependent property to lower the rate of SMC 
proliferation. We were further able to show for the first time, that this effect is certainly 
mediated via the PPAR-γ receptor. Also mediated via this receptor type, genistein can 
decrease the rate of collagen synthesis in SMCs. Thereby it units two important properties to 
decrease the risk of plaques-formation and risk of atherosclerosis and CVD. Compared to 
other known mollecules genistein has a significant higher efficiency apart from oestradiol. 
Oestradiol itself has numerous side effects and is hence not the perfect drug in the treatment 
of atherosclerosis. We were also able to demonstrate throughout all our experiments, that 
there must be something like an optimal dosage by the means of “highest effect at lowest 
rate”. This “watershed” is around levels of 10-50 μmol/l. All the demonstrated experiments 
are in vitro experiments, why the treatment levels cannot be transferred to in vivo setting.  
 
Critics 
 
The experiments shown in this paper are based on ex-vivo models. We investigated certain 
effects of genistein on SMC-cultures. The results mentioned above are a good basis to discuss 
effects of genistein administered to the human body. One problem remains the different 
situation in vivo, where resorption in the digestive system, administration in the 
compartiments of the body and so on could lead to different results in SMCs. It is further 
possible, that other cell types apart from SMCs are involved in the effects on genistein which 
can cause a higher or lower effect compared to the cell culture. To investigate the effects of 
genistein on SMCs in a complex system like the human body, animal experiments can help to 
answer these questions. As the effects of genistein on SMCs are very much dependent on the 
amounts of genistein mollecules in the extracellular milieu it needs to be investigated which 
amounts of genistein are present at the sights of SMC-growth in in-vivo models. 
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Genistein is only one mollecule of the family of phytoestrogens. From the experiments shown 
in this work it is not possible to conclude that other phytoestrogens act in a similar way. It is 
possible that different distribution and metabolism influences the effects of other 
phytoestrogens. Further experiments need to be done to study their differences and 
similarities. Our results proof that the measured parameters are mediated via PPAR-γ 
receptors, because by blocking this receptor and leaving the ERs unblocked at the same time, 
we were not able to measure the effects. ERs obviously do not act like key receptors in 
transmitting these effects, but are more or less irrelevant. This conclusion can only be made 
for genistein while other phytoestrogens need to be studied for their interaction with the 
PPAR-γ receptor. 
 
 
5.3. Perspectives 
 
As already described in the introduction, phytoestrogens are oestrogen-like mollecules, 
binding to estrogen receptors and others. Their side effects are minimal and they show good 
impact in totally different areas like fertility and development [59-62], thyroid function [63-
65], central nervous and immune system [67-70], osteoporosis [71-77] and the cardiovascular 
system [81, 111-119]. This shows the immense complexity in the effects of this group of 
mollecules. Their presence in food (Fig 5.4.1) makes them available to nearly every human 
being to high degrees. After intake they show high levels of absorption and distribution to 
different tissues. Their metabolism and excretion makes them low in risk and practical for 
commom use. Their oestrogen-like effects are well known, also it is still not clear, whether 
they use similar pathways or not.  
In patients with atherosclerosis after menopausal changes, hormon replacement therapy is 
well known to lower the risk of CVD [102, 103], although these results are discussed 
controversly.  
As mentioned above it is therefore very important to invent a treatment for postmenopausal 
women which provides a good cardioprotective effect and does not cause the unwanted side-
effects of oestrogen. We were able to show that one target drug in this struggle is genestein, a 
phytoestrogen which leads to a decreased rate of SMC proliferation and DNA-synthesis as 
well as a decreased collagen synthesis – both mandatory factors in the genesis of 
atherosclerosis. The easy oral application of genistein and other phytoestrogens makes them a 
practical target-drug to fight atherosclerosis. As discussed above, more animal studies are 
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needed to investigate and specify certain effects of genistein on different organs to make it a 
useful and safe drug. With respect to CVD and atherosclerosis it is possible that 
phytoestrogens may replace oestrogens in the therapy of postmenopausal women. 
 
 
Fig. 5.4.1. Classes of phytoestrogens and common dietary sources. 
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genistein level 0 0,1 1 10 50 100
 -GW9662 100 88 78 68 36 28
+GW9662 100 105 105 97 96 93
 -ICI182780 100 90 80 70 43 29
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+ICI182780 100 95 85 65 40 27
        
genistein level 0 0,1 1 10 50 100
 -GW9662 100 98 85 66 40 27
+GW9662 100 100 99 97 96 95
 -ICI182780 100 97 81 65 35 26
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+ICI182780 100 97 81 65 36 27
        
genistein level 0 0,1 1 10 50 100
 -GW9662 100 86 76 64 28 25
+GW9662 100 99,5 98,5 97 95 94
 -ICI182780 100 95 86 60 27 27
C
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+ICI182780 100 97 88 58 25 24
Table 1: DNA synthesis, Collagen synthesis and cell numbers of SMC cultures as percentage of control under 
the influence of different genistein levels (μml/l); shwon with unblocked and blocked PPAR-γ receptor (-
/+GW9662) and blocked and unblocked oestrogen receptor (-/+ICI82780) 
 
Cell number       
Rosiglitazone 0 0,1 1 10 50 100
 -GW9662 100 96 93 84 74 64
+GW9662 100 99 98 97,5 97 95
Table 2: Cell numbers of SMC cultures as percentage of control under the influence of different Rosiglitazone 
levels (μml/l); shwon with unblocked and blocked PPAR-γ receptor (-/+GW9662) 
 
Cell number       
 0 0,1 1 10 50 100
Rosiglitazone 100 96 90 80 70 60
Genistein 100 86 76 64 30 27
Table 3: Cell numbers of SMC cultures as percentage of control under the influence of different Rosiglitazone 
and Genistein levels (μml/l) 
 
Cell number     
 Control Estradiol Rosiglitazone Genistein
 -GW9662 100 53 75 62
+GW9662 100 55 97 90
Table 4: Cell numbers of SMC cultures as percentage of control under the influence of Estradiol, Rosiglitazone 
and Genistein (μml/l)  
 
DNA Synthesis     
 Control Daidzein Equol Resveratrol Genistein 
 -GW9662 100 60 80 70 40 
+GW9662 100 86 80 84 88 
Table 5: DNA synthesis of SMC cultures as percentage of control under the influence of Daidzein, Equol, 
Resveratrol and Genistein (μml/l)  
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